HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure

Retrovirology

Volumn 6, Issue , 2009, Pages

  van Hal, Sebastiaan J ^a   Herring, Belinda ^a   Deris, Zaquan ^a,c   Wang, Bin ^b   Saksena, Nitin K ^b   Dwyer, Dominic E ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTEGRASE; INTEGRASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; ENZYME POLYMORPHISM; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; DRUG EFFECT; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; INTEGRASE INHIBITORS; MUTATION; POLYMORPHISM, GENETIC;

EID: 62149120287     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-12     Document Type: Article

References (7)

1. Rhee SY Liu TF Kiuchi M Zioni R Gifford RJ Holmes SP Shafer RW Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors Retrovirology 2008, 5:74. 2546438 18687142 10.1186/1742-4690-5-74
2. Cooper DA Steigbigel RT Gatell JM Rockstroh JK Katlama C Yeni P Lazzarin A Clotet B Kumar PN Eron JE Schechter M Markowitz M Loutfy MR Lennox JL Zhao J Chen J Ryan DM Rhodes RR Killar JA Gilde LR Strohmaier KM Meibohm AR Miller MD Hazuda DJ Nessly ML DiNubile MJ Isaacs RD Teppler H Nguyen BY BENCHMRK Study Teams Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection N Engl J Med 2008, 359:355-65. 10.1056/ NEJMoa0708978 18650513
3. Steigbigel RT Cooper DA Kumar PN Eron JE Schechter M Markowitz M Loutfy MR Lennox JL Gatell JM Rockstroh JK Katlama C Yeni P Lazzarin A Clotet B Zhao J Chen J Ryan DM Rhodes RR Killar JA Gilde LR Strohmaier KM Meibohm AR Miller MD Hazuda DJ Nessly ML DiNubile MJ Isaacs RD Nguyen BY Teppler H BENCHMRK Study Teams Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 2008, 359:339-54. 10.1056/ NEJMoa0708975 18650512
4. Myers RE Pillay D Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase J Virol 2008, 82:9228-35. 10.1128/JVI.01535-07 18596095
5. Delelis O Malet I Na L Tchertanov L Calvez V Marcelin AG Subra F Deprez E Mouscadet JF The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation Nucleic Acids Res 2009. 19129221
6. Wang B Lau KA Ong LY Shah M Steain MC Foley B Dwyer DE Chew CB Kamarulzaman A Ng KP Saksena NK Complex patterns of the HIV-1 epidemic in Kuala Lumpur, Malaysia: Evidence for expansion of circulating recombinant form CRF33_01B and detection of multiple other recombinants Virology 2007, 367:288-97. 10.1016/j.virol.2007.05.033 17604072
7. Ceccherini-Silberstein F Malet I Fabeni L Svicher V Gori C Dimonte S et al Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients Antivir Ther 2007.